Literature DB >> 1878687

Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study.

D Blaise1, A M Stoppa, D Olive, M Brandely, P Tiberghien, M Attal, J Attal, J Reiffers, F Demeocq, J L Pico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1878687

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

2.  Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.

Authors:  M J Laughlin; G Kirkpatrick; N Sabiston; W Peters; J Kurtzberg
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.